Attenuation of p53 mutant as an approach for treatment Her2-positive cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Breast cancer is a leading cause of cancer death, with heterogeneity in clinical, morphological, and molecular levels.
• Her2-positive breast cancer, comprising 10-15% of cases, presents a worse prognosis due to early relapse and metastasis.
• Existing treatments targeting Her2 receptors face challenges with drug resistance and often co-occur with TP53 mutations.

Purpose of the Study:

• To review the molecular mechanisms of current Her2-receptor-targeted therapies.
• To explore novel combinatorial treatment strategies for Her2-positive breast cancer.
• To discuss the potential of inhibiting mutant p53 in conjunction with Her2-targeted drugs.

Main Methods:

• Review of existing literature on Her2-positive breast cancer molecular mechanisms.
• Analysis of drug resistance pathways in Her2-positive tumors.
• Exploration of therapeutic strategies targeting Her2 receptors and TP53 mutations.

Main Results:

• Her2 receptor signaling, including homo- and heterodimerization and RTK activity, is crucial for cancer cell proliferation.
• Drug resistance is a significant clinical challenge in Her2-positive breast cancer treatment.
• TP53 mutations frequently occur in Her2-positive cancers, worsening patient prognosis.

Conclusions:

• Targeted therapies for Her2-positive breast cancer are effective but limited by resistance.
• Combinatorial approaches, including targeting mutant p53, offer promising new avenues for treatment.
• Further research into inhibiting both Her2 and mutant p53 may overcome resistance and improve survival rates.